KRAS and non-small cell lung carcinoma: Because ER-α is highly targetable by a number of pharmaceutical compounds, to further explore whether ER-α may represent a new drug target for a subgroup of KRAS MT lung cancers, we performed IHC analysis on an independent study set of 90 archived NSCLC samples.